TERT promoter mutation in resectable hepatocellular carcinomas: A strong association with hepatitis C infection and absence of hepatitis B infection

International Journal of Surgery

Volumn 12, Issue 7, 2014, Pages 659-665

  Chen, Yu Ling ^a   Jeng, Yung Ming ^a,b   Chang, Chih Ning ^a   Lee, Hsin Jung ^a   Hsu, Hey Chi ^a   Lai, Po Lin ^b   Yuan, Ray Hwang ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

HCC; Hepatitis B; Hepatitis C; Promoter mutation; TERT

Indexed keywords

ALPHA FETOPROTEIN; BETA CATENIN; GENOMIC DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; MESSENGER RNA; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGE; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA DETERMINATION; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; COMPLICATION; GENETICS; LIVER TUMOR; MIDDLE AGED; MUTATION; RISK FACTOR; SURVIVAL; VIROLOGY; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CORRELATIONAL STUDY; GENE FREQUENCY; GENE SEQUENCE; GENETIC IDENTIFICATION; MUTATION RATE; SENESCENCE; TUMOR RECURRENCE; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; RISK FACTORS; SURVIVAL ANALYSIS; TELOMERASE;

EID: 84902967422     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2014.05.066     Document Type: Article

References (34)

1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576.
2. Yu M.C., Yuan J.M., Govindarajan S., Ross R.K. Epidemiology of hepatocellular carcinoma. Can. J. Gastroenterol. 2000, 14(8):703-709.
3. Hsu H.C., Jeng Y.M., Mao T.L., Chu J.S., Lai P.L., Peng S.Y. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am. J. Pathol. 2000, 157(3):763-770.
4. Hsu H.C., Huang A.M., Lai P.L., Chien W.M., Peng S.Y., Lin S.W. Genetic alterations at the splice junction of p53 gene in human hepatocellular carcinoma. Hepatology 1994, 19(1):122-128.
5. Huang J., Deng Q., Wang Q., Li K.Y., Dai J.H., Li N., et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat. Genet. 2012, 44(10):1117-1121.
6. Guichard C., Amaddeo G., Imbeaud S., Ladeiro Y., Pelletier L., Maad I.B., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012, 44(6):694-698.
7. Fujimoto A., Totoki Y., Abe T., Boroevich K.A., Hosoda F., Nguyen H.H., et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 2012, 44(7):760-764.
8. Günes C., Rudolph K.L. The role of telomeres in stem cells and cancer. Cell 2013, 152(3):390-393.
9. Saini N., Srinivasan R., Chawla Y., Sharma S., Chakraborti A., Rajwanshi A. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status. Liver Int. 2009, 29(8):1162-1170.
10. Härle-Bachor C., Boukamp P. Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(13):6476-6481.
11. Norrback K.F., Roos G. Telomeres and telomerase in normal and malignant haematopoietic cells. Eur. J. Cancer 1997, 33(5):774-780.
12. Shay J.W., Wright W.E. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005, 26(5):867-874.
13. Tahara H., Nakanishi T., Kitamoto M., Nakashio R., Shay J.W., Tahara E., et al. Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res. 1995, 55(13):2734-2736.
14. Kojima H., Yokosuka O., Imazeki F., Saisho H., Omata M. Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology 1997, 112(2):493-500.
15. Liu H., Shi W., Luan F., Xu S., Yang F., Sun W., et al. Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. Virus Genes 2010, 40(2):174-182.
16. Toh S.T., Jin Y., Liu L., Wang J., Babrzadeh F., Gharizadeh B., et al. Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. Carcinogenesis 2013, 34(4):787-798.
17. Zuo Q.P., Liu S.K., Li Z.J., Li B., Zhou Y.L., Guo R., et al. NF-kappaB p65 modulates the telomerase reverse transcriptase in the HepG[U+2082]hepatoma cell line. Eur. J. Pharmacol. 2011, 672(1-3):113-120.
18. Huang F.W., Hodis E., Xu M.J., Kryukov G.V., Chin L., Garraway L.A. Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 339(6122):957-959.
19. Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339(6122):959-961.
20. Killela P.J., Reitman Z.J., Jiao Y., Bettegowda C., Agrawal N., Diaz L.A.J., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(15):6021-6026.
21. Nault J.C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 2013, 4(2218). 10.1038/ncomms3218.
22. Yuan R.H., Jeng Y.M., Chen H.L., Hsieh F.J., Yang C.Y., Lee P.H., et al. Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis. Clin. Cancer Res. 2005, 11(7):2568-2575.
23. Yuan R.H., Jeng Y.M., Chen H.L., Lai P.L., Pan H.W., Hsieh F.J., et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J. Pathol. 2006, 209(4):549-558.
24. Edmonson H.A., Steiner P.E. Primary carcinoma of the liver: a study of 100 among 489,000 necropsies. Cancer (Phila) 1954, 7:462-503.
25. AJCC Cancer Staging Manual 2010, Springer, New York, NY. seventh ed. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti (Eds.).
26. Ding D., Lou X., Hua D., Yu W., Li L., Wang J., et al. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet. 2012, 8(12):e1003065. 10.1371/journal.pgen.
27. Sung W.K., Zheng H., Li S., Chen R., Liu X., Li Y., et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 2012, 44(7):765-769.
28. Paterlini-Bréchot P., Saigo K., Murakami Y., Chami M., Gozuacik D., Mugnier C., et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003, 22(25):3911-3916.
29. Ferber M.J., Montoya D.P., Yu C., Aderca I., McGee A., Thorland E.C., et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003, 22(24):3813-3820.
30. Gai X., Zhao P., Pan Y., Shan H., Yue X., Du J., et al. Hepatitis B virus core protein enhances human telomerase reverse transcriptase expression and hepatocellular carcinoma cell proliferation in a c-Ets2-dependent manner. Int. J. Biochem Cell. Biol. 2013, 45(7):1174-1185.
31. Nordenstedt H., White D.L., El-Serag H.B. The changing pattern of epidemiology in hepatocellular carcinoma. Dig. Liver Dis. 2010, 42(Suppl. 3):S206-S214.
32. Hwang S.J. Hepatitis C virus infection: an overview. J. Microbiol. Immunol. Infect. 2001, 34(4):227-234.
33. Ng J., Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat. Mon. 2012, 12(10 HCC):e7635. 10.5812/hepatmon.7635.
34. Kotoula V., Hytiroglou P., Pyrpasopoulou A., Saxena R., Thung S.N., Papadimitriou C.S. Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers. Liver Int. 2002, 22(1):57-69.